Company Aelis Farma

AELIS

FR0014007ZB4

Pharmaceuticals

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Ratings for Aelis Farma

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 09:52:17 02/05/2024 BST			5-day change	1st Jan Change
13 ^EUR	0.00%		0.00%	-0.76%

04-18	Aelis Farma SA Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder	CI
04-02	Aelis Farma SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Aelis Farma is specialized in the research and development of drugs for the treatment of major disorders of the Central Nervous System (CNS).

The company has 2 products in clinical development, including AEF0117 for cannabis-related disorders (severe dependence, acute psychosis and acute toxicity), and AEF0217 for cognitive deficits (disorders related to Down syndrome, Fragile X syndrome, Subjective Memory Impairment (SMI) and Alzheimer's disease).

Number of employees: 22

EUR in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical Products 100.0 %	8	100.0 %	12	100.0 %	+47.75%

EUR in Million	2022	Weight	2023	Weight	Delta
France 100.0 %	8	100.0 %	12	100.0 %	+47.75%

Managers	Title	Age	Since
Pier Vincenzo Piazza FOU	Founder	63	06/10/13
Marie Line Lefevre DFI	Director of Finance/CFO	-	-
Helle Mengel CTO	Chief Tech/Sci/R&D Officer	-	-
Stéphanie Monlezun COO	Chief Operating Officer	-	-
Léa Floquet LAW	General Counsel	-	31/12/20
Arsène Guekam PRN	Corporate Officer/Principal	-	01-16

Members of the board	Title	Age	Since
Anders Gersel Pedersen CHM	Chairman	73	31/12/19
François Thomas BRD	Director/Board Member	66	31/12/21
Irina Staatz-Granzer BRD	Director/Board Member	64	31/12/21
Karen Linehan BRD	Director/Board Member	65	31/12/21
Pier Vincenzo Piazza FOU	Founder	63	06/10/13
Brahim Guetarni BRD	Director/Board Member	47	31/12/20
Karina Hansen BRD	Director/Board Member	51	31/12/21

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	13,257,762	12,501,162 ( 94.29 %)	0	94.29 %

Name	Equities	%	Valuation
Aquiti Gestion SAS 23.98 %	3,178,578	23.98 %	44 M €
Vincenzo Piazza Pier 20.08 %	2,662,528	20.08 %	37 M €
BPIFrance Investissement SAS 14.04 %	1,860,766	14.04 %	26 M €
UI Investissement SAS 12.10 %	1,604,447	12.10 %	22 M €
IRDI Capital Investissement SAS 6.162 %	817,006	6.162 %	11 M €
INDIVIOR PLC 5.291 %	701,469	5.291 %	10 M €
Gersel Pedersen Anders 0.7995 %	106,000	0.7995 %	1 M €
SG 29 Haussmann SASU 0.1614 %	21,398	0.1614 %	299 272 €
Financière Arbevel SA 0.1345 %	17,832	0.1345 %	249 398 €

Aelis Farma SA

1, rue Lafaurie de Monbadon

33000, Bordeaux

+33 5 57 57 37 70

http://www.aelisfarma.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13 EUR

Average target price

20.67 EUR

Spread / Average Target

+58.97%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
AELIS FARMA	-0.76%	182M
ELI LILLY AND COMPANY	+29.68%	699B
NOVO NORDISK A/S	+25.07%	571B
JOHNSON & JOHNSON	-4.35%	364B
MERCK & CO., INC.	+17.65%	326B
ABBVIE INC.	+3.77%	286B
ASTRAZENECA PLC	+14.68%	236B
NOVARTIS AG	+4.71%	198B
ROCHE HOLDING AG	-12.43%	194B
PFIZER, INC.	-3.79%	154B

Other Pharmaceuticals